bluebird bio Revenue and Competitors

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • bluebird bio's estimated annual revenue is currently $53.6M per year.(i)
  • bluebird bio received $632.5M in venture funding in July 2018.
  • bluebird bio's estimated revenue per employee is $90,778
  • bluebird bio's total funding is $484M.
  • bluebird bio's current valuation is $612M. (January 2022)

Employee Data

  • bluebird bio has 591 Employees.(i)
  • bluebird bio grew their employee count by 6% last year.

bluebird bio's People

Chief Financial OfficerReveal Email/Phone
SVP Marketing, Sales, Strategy and AnalyticsReveal Email/Phone
Head, US BusinessReveal Email/Phone
VP Process, Data, and Manufacturing Sciences (Severe Genetic Diseases)Reveal Email/Phone
VP Head Information Technology and InformaticsReveal Email/Phone
SVP QualityReveal Email/Phone
VP, Commercial, OncologyReveal Email/Phone
VP, Value Demonstration and Access StrategyReveal Email/Phone
VP, Analytical DevelopmentReveal Email/Phone
VP, Oncology Corporate DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

What Is bluebird bio?

We are leading the gene therapy revolution. Our integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing - providing us with the potential to treat, and hopefully cure, a broad range of serious diseases. We have a lot of energy, and it's not just the abundance of coffee that keeps us going. Find out what sparks our excitement and inspires us every day.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





bluebird bio News

2022-04-20 - Bluebird bio's gene therapy Zynteglo could have high price ...

Bluebird bio's beta thalassemia gene therapy treatment Zynteglo might have some grounds to support an anticipated high price point,...

2022-04-17 - Stock Down 98% From Peak, Bluebird Bio Could Run Out Of Cash

Investment climate for publicly-traded biotech stocks poor; Despite recent layoffs, Bluebird Bio's cash position is weak; Bluebird Bio's revenue...

2022-03-30 - Bluebird bio cuts 30% of its workforce as gene therapy dreams ...

The multiple R&D, regulatory and commercialization setbacks have hit home for bluebird bio. Hoping to keep the business afloat, the gene therapy specialist...

2021-09-08 - bluebird bio : Secures $75 Million in Private Placement Equity Financing

bluebird bio, Inc. (NASDAQ: BLUE) announced today that it has entered into an agreement for a $75 million private placement of common stock and common stock equivalents with a healthcare investment fund selected as part of a competitive process. Proceeds from the financing will support ongoing R ...

2021-06-07 - BLUEBIRD BIO, INC. Bluebird bio : Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies (Form 8-K)

bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies CAMBRIDGE, Mass. - (BUSINESS WIRE) - June 7, 2021- bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Ph ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

bluebird bio Funding

DateAmountRoundLead InvestorsReference
2011-04-21$30.0MUndisclosedARCH Venture Partners, Third Rock VenturesArticle
2012-07-26$60.0MDDeerfield Partners, RA CapitalArticle
2013-06-03$60.0MDDeerfield Partners, RA CapitalArticle
2015-06-25$575.0MBofA Merrill LynchArticle
2016-12-08$200.0MUndisclosedGoldman, Sachs & CoArticle
2017-06-28$350.0MUndisclosedGoldman Sachs & Co. LLCArticle